COMPARISON OF GLYCEMIC CONTROL ACTVITY OF SGLT2 INHIBITORS AND SULPHONYLUREAS IN PATIENTS OF DECOMPENSATED LIVER DISEASE
DOI:
https://doi.org/10.71000/c09ret02Keywords:
Albumin, Antidiabetic Agents, , Body Weight, Decompensated Liver Cirrhosis, Glycemic Control, Hypoglycemia, Sodium-Glucose Transporter 2 InhibitorsAbstract
Background: Diabetes mellitus (DM) is a well-established risk factor for worsening structural and biochemical parameters in decompensated chronic liver disease (DCLD), a condition with significant global morbidity and mortality (1,2). Poor glycemic control in DCLD increases the likelihood of complications such as hepatic encephalopathy, gastrointestinal bleeding, and ascites. Achieving optimal glycemic control is essential to slow disease progression, reduce complications, and improve survival outcomes. The selection of appropriate second-line oral antidiabetic drugs (ADDs) in this population remains a matter of clinical debate.
Objective: To compare the efficacy and safety of sulphonylureas (SU) and sodium-glucose co-transporter 2 (SGLT2) inhibitors in achieving glycemic control in patients with DCLD.
Methods: This longitudinal cross-sectional study was conducted at Combined Military Hospital Jhelum from May 2024 to January 2025. Using non-probability convenience sampling, 100 patients with DM and DCLD for at least one-year, inadequate glycemic control on metformin, and no major comorbidities were enrolled. Patients were assigned to either SU (n=50) or SGLT2 inhibitor (n=50) therapy. Baseline and 3-month follow-up assessments included fasting blood glucose (FBG), post-prandial glucose (PPG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine, albumin, cholesterol, body weight, and hypoglycemia incidence. Data analysis was performed using SPSS v25 with chi-square test, considering p<0.05 as statistically significant.
Results: Baseline characteristics were comparable between SU and SGLT2 groups in age (59.40±9.09 vs 59.96±9.54 years), BMI (29.32±1.53 vs 28.90±2.31 kg/m²), duration of DM (9.70±3.46 vs 10.00±1.93 years), and DCLD (9.16±2.92 vs 9.66±3.10 years). At 3 months, both groups showed reductions in FBG (204.80±25.54 to 175.50±28.32 vs 214.76±26.17 to 169.70±27.88 mg/dL, p=0.305) and PPG (238.02±28.99 to 222.78±25.95 vs 246.10±29.19 to 225.04±25.12 mg/dL, p=0.659), without significant intergroup difference. Hypoglycemia was more frequent in the SU group (16% vs 4%, p=0.046). ALT, albumin, and body weight changes were non-significant between groups.
Conclusion: Both SU and SGLT2 inhibitors demonstrated comparable glycemic control in DCLD, though the lower hypoglycemia incidence with SGLT2 inhibitors suggests a safety advantage in patients with prior hypoglycemia.
References
Arvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G. Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2024 Jan 1;18(1):102935.
Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational gastroenterology and hepatology. 2020 Apr 5;5:16.
García-Compeán D, Orsi E, Kumar R, Gundling F, Nishida T, Villarreal-Pérez JZ, Del Cueto-Aguilera ÁN, González-González JA, Pugliese G. Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives. World journal of gastroenterology. 2022 Feb 28;28(8):775.
Nath P, Anand AC. Hepatogenous diabetes: a primer. Journal of clinical and experimental hepatology. 2021 Sep 1;11(5):603-15.
Jang H, Kim Y, Lee DH, Joo SK, Koo BK, Lim S, Lee W, Kim W. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA internal medicine. 2024 Apr 1;184(4):375-83.
Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clinical and molecular hepatology. 2020 Aug 14;26(4):430.
Augusto GA, Cassola N, Dualib PM, Saconato H, Melnik T. Sodium‐glucose cotransporter‐2 inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews. Diabetes, Obesity and Metabolism. 2021 Oct;23(10):2289-302.
Hassan, Kamran & Shabbir, Hamza & Nouman, Talha & Azfar, Hanan & Bano, Shahar & khan, Kashmala & Ali, Amir & Asim, Hafiz. (2025). Comparative Efficacy of Low-Level Laser Therapy and Platelet-Rich Plasma Injection on Pain, Tendon Thickness, and Functional Outcomes in Athletes with Patellar Tendinopathy: A 12-Week Randomized Controlled Trial. Journal of Health, Wellness, and Community Research. e530. 10.61919/swzta320.
Benjamin S, Ramanjaneya M, Butler AE, Janjua I, Paramba F, Palaki J, Kubaisi AA, Chandra P, Abdalhakam I, Massodi NA. Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels. Frontiers in Clinical Diabetes and Healthcare. 2021 Oct 12;2:733693.
Chou OH, Ning J, Chiu Chan RN, Chung CT, Huang H, Ng K, Dee EC, Lee S, Kaewdech A, Liu T, Jing F. Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study. medRxiv. 2022 Aug 17:2022-08.
Cho HJ, Lee E, Kim SS, Cheong JY. SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea. Scientific Reports. 2024 Apr 29;14(1):9761.
Lee CH, Mak LY, Tang EH, Lui DT, Mak JH, Li L, Wu T, Chan WL, Yuen MF, Lam KS, Wong CK. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong. Hepatology. 2023 Nov 1;78(5):1569-80.
Puri P, Kotwal N. An approach to the management of diabetes mellitus in cirrhosis: a primer for the hepatologist. Journal of Clinical and Experimental Hepatology. 2022 Mar 1;12(2):560-74.
Yen FS, Lai JN, Wei JC, Chiu LT, Hwu CM, Hou MC, Hsu CC. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis. Plos one. 2020 Dec 14;15(12):e0243783.
Yen FS, Hsu CC, Wei JC, Hou MC, Hwu CM. Selection and warning of evidence-based antidiabetic medications for patients with chronic liver disease. Frontiers in Medicine. 2022 Feb 16;9:839456.
Dissanayake P, Wijenayake UN, Dematapitiya C, Pathmanathan S, Sumanatilleke M, Bulugahapitiya U. Use of sulphonylurea in type 2 diabetes mellitus and incident risk of Hepatocellular Carcinoma: Are we safe to prescribe?. Sri Lanka Journal of Diabetes Endocrinology and Metabolism. 2022 Dec 8;13(2).
Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World Journal of Hepatology. 2020 Sep 27;12(9):533.
Puri P, Kotwal N. An approach to the management of diabetes mellitus in cirrhosis: a primer for the hepatologist. Journal of Clinical and Experimental Hepatology. 2022 Mar 1;12(2):560-74.
Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Eslam M, Wong GL, George J, Romero-Gomez M, Adams LA. Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis–related, Child–Pugh A cirrhosis. Clinical Gastroenterology and Hepatology. 2021 Jan 1;19(1):136-45.
Shabbir, Hamza & Shafi, Muhammad & Mushtaq, Muhammad. (2025). Effects of Inspiratory Muscle Training on Respiratory Strength and Functional Capacity in Post-operative Patients with Scoliosis during Maximum Protection Phase. The Healer Journal of Physiotherapy and Rehabilitation Sciences. 5. 72-80. 10.55735/hjprs.v5i2.366.
Liang LY, Wong VW, Hui VW, Yip TC, Tse YK, Lui GC, Chan HL, Wong GL. Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. GastroHep. 2021 Jul;3(4):261-9.
Yen FS, Lai JN, Wei JC, Chiu LT, Hwu CM, Hou MC, Hsu CC. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis. Plos one. 2020 Dec 14;15(12):e0243783.
Kinoshita T, Shimoda M, Nakashima K, Fushimi Y, Hirata Y, Tanabe A, Tatsumi F, Hirukawa H, Sanada J, Kohara K, Irie S. Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study. Journal of diabetes investigation. 2020 Nov;11(6):1612-22.
Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, Tanaka T, Goto H, Nakano Y, Iida N, Arai K. Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized, Open-Label Trial Study.
Braet C, Agha YH, Taleb A, Buess C, Millard J. Sulfonylurea-induced hypoglycemia in a patient with cirrhosis. Cureus. 2020 Jun 8;12(6).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Zaboor Ahmed, Waheed Ahmed , Muhammad Usman Khan, Farah Rao, Syed Haider tirmizi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
